A Pilot study of allogeneic cellular therapy for patients with advanced hematologic malignancies

Daniel J. Medina, Mecide Gharibo, Philip Savage, Alan Cohler, Mercy Kuriyan, Binaifer Balsara, Monika Anand, Dale Schaar, Tracy Krimmel, Kara Saggiomo, Jacqueline Manago, Lois Talty, Liesel Dudek, Stephanie Grospe, Arnold Rubin, Roger K. Strair

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

Allogeneic hematopoietic stem cell transplantation provides curative therapy for some patients with advanced hematologic malignancies. Disease response after allogeneic transplant is, at least in part, mediated by donor immune cells. In this report we describe a cellular therapy using haploidentical peripheral blood stem cells administered after very low dose total body irradiation (TBI) (100 cGy). The donor cells were anticipated to be rejected, so no graft-versus-host (GVHD) prophylaxis was used. Patients with persistent disease beyond 8 weeks could be further treated with infusions of irradiated haploidentical donor cells. Of the 10 patients enrolled in the study, durable engraftment of allogeneic cells was seen in one patient. Two patients with resistant relapsed acute myelogenous leukemia (AML) had a disease response. Analysis of T cell reactivity from one patient who achieved a complete response but did not have durable engraftment of donor cells indicated that disease response was associated with the generation of host-derived anti-leukemic cytotoxic CD8+ T cells that reacted with an AML-associated proteinase 3 epitope. Results from this patient suggest that allogeneic therapy induced a host anti-tumor response associated with cytotoxic T cells reactive with a low affinity self-antigen.

Original languageEnglish (US)
Pages (from-to)1842-1848
Number of pages7
JournalLeukemia Research
Volume32
Issue number12
DOIs
StatePublished - Dec 2008

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Keywords

  • Cellular therapy
  • Cytotoxic T cells
  • Hematologic malignancies
  • Proteinase 3

Fingerprint

Dive into the research topics of 'A Pilot study of allogeneic cellular therapy for patients with advanced hematologic malignancies'. Together they form a unique fingerprint.

Cite this